Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11754MR)

This product GTTS-WQ11754MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11754MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9894MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA KB001-A
GTTS-WQ8268MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HM10560A
GTTS-WQ643MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 8c10
GTTS-WQ8432MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HSP90mab
GTTS-WQ10961MR IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MCAF-5352A
GTTS-WQ3021MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ12833MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ONC-005
GTTS-WQ13098MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-03446962
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW